Smead

With an average five-year Morningstar Rating of 4.7 stars across its open-end and exchange-traded products, the firm has demonstrated its ability to deploy capital successfully for investors. A negative contributor to Smead's rating is its lower-than-average portfolio management retention over the past five years, as elevated turnover bears watching. Smead open-end and exchange-traded products are priced, on average, among the second most-expensive quintile of similarly distributed strategies. This higher expense profile of its funds creates a larger performance hurdle and contributes negatively to Smead's rating.